Sigma Planning Corp Has $694,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Sigma Planning Corp lifted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 50.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,987 shares of the biopharmaceutical company’s stock after purchasing an additional 10,712 shares during the quarter. Sigma Planning Corp’s holdings in Catalyst Pharmaceuticals were worth $694,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 8,495,580 shares of the biopharmaceutical company’s stock valued at $206,018,000 after purchasing an additional 64,486 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Catalyst Pharmaceuticals by 11.9% during the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after buying an additional 333,100 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Catalyst Pharmaceuticals by 6.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,326,771 shares of the biopharmaceutical company’s stock worth $32,174,000 after buying an additional 79,846 shares during the last quarter. Invesco Ltd. lifted its position in shares of Catalyst Pharmaceuticals by 41.7% in the first quarter. Invesco Ltd. now owns 1,199,627 shares of the biopharmaceutical company’s stock worth $29,091,000 after buying an additional 352,776 shares during the last quarter. Finally, Allianz Asset Management GmbH boosted its stake in shares of Catalyst Pharmaceuticals by 49.5% during the 2nd quarter. Allianz Asset Management GmbH now owns 1,037,811 shares of the biopharmaceutical company’s stock worth $22,520,000 after acquiring an additional 343,686 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 1.9%

CPRX opened at $21.39 on Friday. The business has a 50 day moving average of $20.50 and a 200-day moving average of $21.79. The stock has a market capitalization of $2.62 billion, a price-to-earnings ratio of 12.96, a P/E/G ratio of 0.84 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $26.58.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Monday, September 25th. The biopharmaceutical company reported $0.28 EPS for the quarter. Catalyst Pharmaceuticals had a net margin of 37.36% and a return on equity of 40.78%. The firm had revenue of $53.11 million during the quarter. Equities analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.9 EPS for the current year.

Catalyst Pharmaceuticals announced that its board has initiated a share repurchase plan on Wednesday, October 1st that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the biopharmaceutical company to purchase up to 8.3% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CPRX. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Oppenheimer reissued an “outperform” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday. Citigroup boosted their price objective on shares of Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday. Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $33.14.

Insider Activity at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 26,000 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $20.20, for a total value of $525,200.00. Following the completion of the sale, the director owned 379,620 shares in the company, valued at approximately $7,668,324. This trade represents a 6.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian Elsbernd sold 30,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $20.30, for a total value of $609,000.00. Following the sale, the insider directly owned 271,039 shares in the company, valued at approximately $5,502,091.70. This trade represents a 9.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 243,970 shares of company stock worth $4,927,241 over the last ninety days. Corporate insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.